000180916 001__ 180916
000180916 005__ 20240229145635.0
000180916 0247_ $$2doi$$a10.1093/neuonc/noac188
000180916 0247_ $$2ISSN$$a1522-8517
000180916 0247_ $$2ISSN$$a1523-5866
000180916 0247_ $$2altmetric$$aaltmetric:133462759
000180916 0247_ $$2pmid$$apmid:35908833
000180916 037__ $$aDKFZ-2022-01641
000180916 082__ $$a610
000180916 1001_ $$aRudà, Roberta$$b0
000180916 245__ $$aEano-Euracan-Sno Guidelines on Circumscribed Astrocytic GLIOMAS, Glioneuronal and Neuronaltumors
000180916 260__ $$aOxford$$bOxford Univ. Press$$c2022
000180916 3367_ $$2DRIVER$$aarticle
000180916 3367_ $$2DataCite$$aOutput Types/Journal article
000180916 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1670328538_13268$$xReview Article
000180916 3367_ $$2BibTeX$$aARTICLE
000180916 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000180916 3367_ $$00$$2EndNote$$aJournal Article
000180916 500__ $$a2022 Dec 1;24(12):2015-2034
000180916 520__ $$aIn the new WHO 2021 Classification of CNS Tumors the chapter “Circumscribed astrocytic gliomas, glioneuronal and neuronal tumors” encompasses several different rare tumor entities, which occur more frequently in children, adolescents and young adults. The Task Force has reviewed the evidence of diagnostic and therapeutic interventions, which is low particularly for adult patients, and draw recommendations accordingly. Tumor diagnosis, based on WHO 2021, is primarily performed using conventional histological techniques; however, molecular workup is important for differential diagnosis, in particular DNA methylation profiling for the definitive classification of histologically unresolved cases. Molecular factors are increasingly of prognostic and predictive importance. MRI finding are non specific, but for some tumors are characteristic and suggestive. Gross total resection, when feasible, is the most important treatment in terms of prolonging survival and achieving long-term seizure control. Conformal radiotherapy should be considered in grade 3 and incompletely resected grade 2 tumors. In recurrent tumors reoperation and radiotherapy, including stereotactic radiotherapy, can be useful. Targeted therapies may be used in selected patients: BRAF and MEK inhibitors in pilocytic astrocytomas, pleomorphic xanthoastrocytomas, and gangliogliomas when BRAF altered, and mTOR inhibitor everolimus in subependymal giant cells astrocytomas .Sequencing to identify molecular targets is advocated for diagnostic clarification and to direct potential targeted therapies.
000180916 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000180916 588__ $$aDataset connected to CrossRef, Journals: inrepo02.dkfz.de
000180916 7001_ $$0P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aCapper, David$$b1$$udkfz
000180916 7001_ $$aWaldman, Adam D$$b2
000180916 7001_ $$00000-0002-1652-9844$$aPallud, Johan$$b3
000180916 7001_ $$aMinniti, Giuseppe$$b4
000180916 7001_ $$aKaley, Thomas J$$b5
000180916 7001_ $$00000-0002-6832-6539$$aBouffet, Eric$$b6
000180916 7001_ $$0P:(DE-HGF)0$$aTabatabai, Ghazaleh$$b7
000180916 7001_ $$aAronica, Eleonora$$b8
000180916 7001_ $$aJakola, Asgeir S$$b9
000180916 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b10$$udkfz
000180916 7001_ $$aSchiff, David$$b11
000180916 7001_ $$aLassman, Andrew B$$b12
000180916 7001_ $$aSolomon, David A$$b13
000180916 7001_ $$00000-0002-9204-7038$$aSoffietti, Riccardo$$b14
000180916 7001_ $$00000-0002-1748-174X$$aWeller, Michael$$b15
000180916 7001_ $$00000-0003-3541-2315$$aPreusser, Matthias$$b16
000180916 7001_ $$00000-0001-5290-1204$$aIdbaih, Ahmed$$b17
000180916 7001_ $$aWen, Patrick Y$$b18
000180916 7001_ $$avan den Bent, Martin J$$b19
000180916 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noac188$$gp. noac188$$n12$$p2015-2034$$tNeuro-Oncology$$v24$$x1522-8517$$y2022
000180916 909CO $$ooai:inrepo02.dkfz.de:180916$$pVDB
000180916 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000180916 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000180916 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000180916 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000180916 9141_ $$y2022
000180916 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000180916 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000180916 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-08$$wger
000180916 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-08
000180916 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-08
000180916 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-08
000180916 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-08
000180916 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2021$$d2022-11-08
000180916 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-08
000180916 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bNEURO-ONCOLOGY : 2021$$d2022-11-08
000180916 9201_ $$0I:(DE-He78)BE01-20160331$$kBE01$$lDKTK BE zentral$$x0
000180916 9201_ $$0I:(DE-He78)TU01-20160331$$kTU01$$lDKTK TU zentral$$x1
000180916 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x2
000180916 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000180916 980__ $$ajournal
000180916 980__ $$aVDB
000180916 980__ $$aI:(DE-He78)BE01-20160331
000180916 980__ $$aI:(DE-He78)TU01-20160331
000180916 980__ $$aI:(DE-He78)B062-20160331
000180916 980__ $$aI:(DE-He78)HD01-20160331
000180916 980__ $$aUNRESTRICTED